利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.024 秒)

    Quantifying the impact of network latency on the end-to-end response time of distributed applications
    2.
    发明授权
    Quantifying the impact of network latency on the end-to-end response time of distributed applications 有权
    量化网络延迟对分布式应用程序端到端响应时间的影响

    公开(公告)号：US08073655B2

    公开(公告)日：2011-12-06

    申请号：US12321623

    申请日：2009-01-23

    申请人： Shuyi Chen ,  William Sanders ,  Matti Hiltunen ,  Kaustubb Joshi ,  Richard Schlichting

    发明人： Shuyi Chen ,  William Sanders ,  Matti Hiltunen ,  Kaustubb Joshi ,  Richard Schlichting

    IPC分类号： G06F11/30

    CPC分类号： H04L43/10 ,  H04L43/0852

    摘要： A method for measuring system response sensitivity, using live traffic and an analysis that converts randomly arriving stimuli and reactions to the stimuli to mean measures over chosen intervals, thereby creating periodically occurring samples that are processed. The system is perturbed in a chosen location of the system in a manner that is periodic with frequency p, and the system's response to arriving stimuli is measured at frequency p. The perturbation, illustratively, is with a square wave pattern.

    摘要翻译： 一种用于测量系统响应灵敏度的方法，使用实时流量和将随机到达的刺激和反应转换为刺激的分析来表示所选间隔的测量，从而产生周期性地发生的被处理的样本。 在系统的选定位置以与频率p周期性的方式扰动系统，并且系统对到达刺激的响应在频率p处被测量。 例如，扰动是以方波模式。

    Cysteinyl compounds, compositions and methods of use
    4.
    发明授权
    Cysteinyl compounds, compositions and methods of use 有权
    半胱氨酰化合物，组合物和使用方法

    公开(公告)号：US08461204B2

    公开(公告)日：2013-06-11

    申请号：US13566839

    申请日：2012-08-03

    申请人： Jeffry B. Stock ,  Maxwell Stock ,  Keshava Rapole ,  Seung-Yub Lee ,  Michael Voronkov ,  Eduardo Perez ,  Joel Gordon ,  Shuyi Chen

    发明人： Jeffry B. Stock ,  Maxwell Stock ,  Keshava Rapole ,  Seung-Yub Lee ,  Michael Voronkov ,  Eduardo Perez ,  Joel Gordon ,  Shuyi Chen

    IPC分类号： A61K31/198 ,  C07C323/24 ,  A61K31/197 ,  C07C323/59

    CPC分类号： A61K31/197 ,  C07C323/59

    摘要： Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).

    摘要翻译： 除此之外，本发明提供能够有效抑制嗜中性粒细胞，巨噬细胞和血小板中G蛋白或GPCR介导的炎症反应的新型化合物。 特别地，本发明的化合物作为水肿抑制剂，红斑抑制剂和MPO抑制剂（髓过氧化物酶），含有相同化合物的药物组合物及其用于治疗可能受益于水肿，红斑和MPO的疾病的用途 抑制，如炎症（急性或慢性），哮喘，自身免疫性疾病和慢性阻塞性肺疾病（COPD）（例如肺气肿，慢性支气管炎和小气道疾病等），免疫系统的炎症反应，皮肤疾病 例如，对于患有酒渣鼻，特应性皮炎，脂溢性皮炎，牛皮癣的患者，肠易激综合征（例如，Chron氏病和溃疡性结肠炎等）以及中枢神经系统疾病（例如帕金森病）的患者减少急性皮肤刺激。

    SILICON-BASED ANODES FOR HIGH ENERGY-DENSITY, HIGH CYCLE-LIFE LITHIUM-ION BATTERY
    5.
    发明公开
    SILICON-BASED ANODES FOR HIGH ENERGY-DENSITY, HIGH CYCLE-LIFE LITHIUM-ION BATTERY 审中-公开

    公开(公告)号：US20230163282A1

    公开(公告)日：2023-05-25

    申请号：US17455810

    申请日：2021-11-19

    申请人： Zhigang Lin ,  Shuyi Chen ,  Chunhu Tan

    发明人： Zhigang Lin ,  Shuyi Chen ,  Chunhu Tan

    IPC分类号： H01M4/38 ,  H01M4/62 ,  H01M4/505 ,  H01M4/525 ,  H01M4/04

    CPC分类号： H01M4/386 ,  H01M4/625 ,  H01M4/505 ,  H01M4/525 ,  H01M4/0471 ,  H01M4/043 ,  H01M4/0416

    摘要： A high-energy-density, high-cycling-life Si-based anode is used for rechargeable Lithium-ion batteries with either solid-state electrolyte or currently commercialized liquid electrolyte. The Si-based anodes include a silicon-based active material, conductive agent(s), and polymer(s) that act as binder(s). The silicon-based active material includes silicon, graphite, metallic or non-metallic oxide, and/or a polymer. The electrode has a specific capacity of at least 2328 mAh/g when cycled at a charge-discharge rate of about 0.5 C and 3245 mAh/g at 0.05 C. Sheets of the Si-based electrode are processable with a well-established industrial process that is cost-effective, scalable, and compatible with currently used Li-ion production lines. A lithium electrochemical pouch cell is manufactured with the Si-based anode sheet with either a liquid electrolyte or a solid-state electrolyte to offer high energy density, long cycle life, and high charge/discharge rates.

    Rate adaptation in a communication system
    8.
    发明授权
    Rate adaptation in a communication system 有权
    通信系统中的速率调整

    公开(公告)号：US08203940B1

    公开(公告)日：2012-06-19

    申请号：US13250750

    申请日：2011-09-30

    申请人： Yuan Yuan ,  Shuyi Chen ,  C. Philip Gossett ,  Jeremy Thorpe

    发明人： Yuan Yuan ,  Shuyi Chen ,  C. Philip Gossett ,  Jeremy Thorpe

    IPC分类号： G01R31/08 ,  G06F11/00 ,  G08C15/00 ,  H04J1/16 ,  H04J3/14 ,  H04L1/00 ,  H04L12/26 ,  H04J3/16 ,  H04J3/22

    CPC分类号： H04W72/082 ,  H04L1/0002 ,  H04L1/203 ,  H04L41/5022 ,  H04L43/0823 ,  H04L47/10 ,  H04L47/263 ,  H04W24/08 ,  H04W28/04 ,  Y02D50/10

    摘要： In general, the subject matter described in this specification can be embodied in methods, systems, and program products for adapting data rate in a communication system. A receiving device receives a data transmission at an initial data rate. The device determines, based on an error rate of the data transmission at the initial data rate, that a first criterion is satisfied for requesting an increase in the data transmission. The device requests that a transmitting device increase the data transmission from the initial data rate to the first subsequent data rate. The device determines, based on an error rate of the data transmission at the first subsequent data rate, whether a second criterion is satisfied for maintaining the first subsequent data rate. The device maintains, if the second criterion is determined to be satisfied, a state of the device for receiving the data transmission at the first subsequent data rate.

    摘要翻译： 通常，本说明书中描述的主题可以体现在用于适应通信系统中的数据速率的方法，系统和程序产品中。 接收设备以初始数据速率接收数据传输。 该设备基于初始数据速率的数据传输的错误率确定满足用于请求数据传输增加的第一标准。 设备请求发送设备将数据传输从初始数据速率增加到第一后续数据速率。 该设备基于在第一后续数据速率下的数据传输的错误率来确定是否满足用于维持第一后续数据速率的第二标准。 如果确定满足第二标准，则设备保持用于以第一后续数据速率接收数据传输的设备的状态。

    Cysteinyl compounds, compositions and methods of use
    9.
    发明申请
    Cysteinyl compounds, compositions and methods of use 有权
    半胱氨酰化合物，组合物和使用方法

    公开(公告)号：US20120328540A1

    公开(公告)日：2012-12-27

    申请号：US13566839

    申请日：2012-08-03

    申请人： Jeffry B. Stock ,  Maxwell Stock ,  Keshava Rapole ,  Seung-Yub Lee ,  Michael Voronkov ,  Eduardo Perez ,  Joel Gordon ,  Shuyi Chen

    发明人： Jeffry B. Stock ,  Maxwell Stock ,  Keshava Rapole ,  Seung-Yub Lee ,  Michael Voronkov ,  Eduardo Perez ,  Joel Gordon ,  Shuyi Chen

    IPC分类号： A61K31/197 ,  A61P17/00 ,  A61P17/14 ,  A61P17/12 ,  A61P29/00 ,  A61P17/08 ,  A61P17/06 ,  A61P37/08 ,  A61P19/04 ,  A61P19/02 ,  A61P31/00 ,  A61P17/10 ,  A61P31/04 ,  A61P17/02 ,  A61Q17/04 ,  C07C321/08

    CPC分类号： A61K31/197 ,  C07C323/59

    摘要： Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, the compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).

    摘要翻译： 除此之外，本发明提供能够有效抑制嗜中性粒细胞，巨噬细胞和血小板中G蛋白或GPCR介导的炎症反应的新型化合物。 特别地，本发明的化合物作为水肿抑制剂，红斑抑制剂和MPO抑制剂（髓过氧化物酶），含有相同化合物的药物组合物及其用于治疗可能受益于水肿，红斑和MPO的疾病的用途 抑制，如炎症（急性或慢性），哮喘，自身免疫性疾病和慢性阻塞性肺疾病（COPD）（例如肺气肿，慢性支气管炎和小气道疾病等），免疫系统的炎症反应，皮肤疾病 例如，对于患有酒渣鼻，特应性皮炎，脂溢性皮炎，牛皮癣的患者，肠易激综合征（例如，Chron氏病和溃疡性结肠炎等）以及中枢神经系统疾病（例如帕金森病）的患者减少急性皮肤刺激。